Other4

Vivos Therapeutics, Inc.

Total Value

$89.2K

Filing Date

Sep 18, 2026

1 transactions

Trade Summary

On Jun 30, 2026, Huntsman Ronald Kirk, Chief Executive Officer, Director, reported $89.2K of Vivos Therapeutics, Inc. (VVOS) across 1 transactions. The filing covers Preferred Stock and reflects balanced net activity of $0. Reported prices ranged from $0.46 to $0.58. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Huntsman Ronald Kirk
Role: Chief Executive Officer, Director
Location: LITTLETON, CO

Filing Details

Filing Date: Sep 18, 2026
Transaction Date: Jun 30, 2026
Accession Number: 0001493152-26-043383
Form Type: 4

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Jun 30, 2026	Preferred Stock	85,910	$0.58	Other	$50.0K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Jun 30, 2026	VVOS derivative	85,910	$0.46	Other	$39.2K

Want live alerts when Huntsman Ronald Kirk trades again?

Download Insider Trades to track VVOS, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Shares held by Coronado V Partners, LLC, of which the Reporting Person is a member and manager.
(F2)On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC ("V-Co 4"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein.
(F3)Represents employee stock options granted on various dates, with exercise prices ranging from $2.38 to $81.75 and expiration dates ranging from February 25, 2027 to September 7, 2034, and also reflects the expiry of 5,001 stock options granted June 16, 2021 that were previously reported on the Reporting Person's Form 4 filed on November 27, 2024, which expired unexercised on June 26, 2026. Table II reports the earliest expiration dates (02/25/2027).

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huntsman Ronald Kirk

(Last)

(First)

(Middle)

7921 SOUTHPARK PLAZA,

SUITE 210

(Street)

LITTLETON

80120

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vivos Therapeutics, Inc. [ VVOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								3,461	D
Common Stock								69,600	I	See footnote⁽¹⁾
Preferred Stock	06/30/2026		J		85,910	A	$0.582	85,910	I	See footnote⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrant (Right to Buy)	$0.456	06/30/2026		J		85,910		06/30/2026	06/30/2031	Common Stock	85,910	$0.582	85,910	I	See footnote⁽²⁾
Stock Options (Right to Buy)⁽³⁾	⁽³⁾							09/18/2026	02/25/2027⁽³⁾	Common Stock	359,754		359,754	D

Explanation of Responses:

1. Shares held by Coronado V Partners, LLC, of which the Reporting Person is a member and manager.

2. On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC ("V-Co 4"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein.

3. Represents employee stock options granted on various dates, with exercise prices ranging from $2.38 to $81.75 and expiration dates ranging from February 25, 2027 to September 7, 2034, and also reflects the expiry of 5,001 stock options granted June 16, 2021 that were previously reported on the Reporting Person's Form 4 filed on November 27, 2024, which expired unexercised on June 26, 2026. Table II reports the earliest expiration dates (02/25/2027).

	/s/ Bradford K. Amman as attorney-in-fact for Ronald Kirk Huntsman	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001493152-26-043383.

Vivos Therapeutics, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when Huntsman Ronald Kirk trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4